Northwest & Ethical Investments L.P. Has $1.81 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Northwest & Ethical Investments L.P. increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 209.0% during the fourth quarter, HoldingsChannel reports. The fund owned 43,466 shares of the company’s stock after buying an additional 29,398 shares during the period. Northwest & Ethical Investments L.P.’s holdings in Moderna were worth $1,807,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in MRNA. Allworth Financial LP increased its stake in Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after buying an additional 281 shares during the last quarter. Howard Capital Management Inc. boosted its holdings in shares of Moderna by 3.1% during the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after buying an additional 297 shares during the period. Larson Financial Group LLC boosted its holdings in shares of Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after buying an additional 317 shares during the period. Empowered Funds LLC boosted its holdings in shares of Moderna by 6.6% during the 3rd quarter. Empowered Funds LLC now owns 5,199 shares of the company’s stock worth $347,000 after buying an additional 322 shares during the period. Finally, Commonwealth Equity Services LLC boosted its holdings in shares of Moderna by 0.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company’s stock worth $3,099,000 after buying an additional 345 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Performance

NASDAQ MRNA opened at $32.66 on Friday. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The company has a 50-day simple moving average of $34.91 and a 200 day simple moving average of $46.05. The company has a market capitalization of $12.60 billion, a PE ratio of -3.52 and a beta of 1.86.

Analysts Set New Price Targets

MRNA has been the subject of a number of recent research reports. Morgan Stanley cut their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a report on Wednesday, January 15th. Barclays cut shares of Moderna from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Leerink Partners dropped their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. UBS Group dropped their target price on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Friday. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.